Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844980 | 0.86 | CYP2A6 (0.56) | CYP2A6TSHRCYP1A2PAX8ALDH1A1 | |
| SCHEMBL5610250 | 0.82 | CYP2A6 (0.52) | CYP2A6TSHRCYP1A2PAX8ALDH1A1 | |
| SCHEMBL31603822 | 0.82 | CYP2A6 (0.52) | CYP2A6TSHRCYP1A2PAX8ALDH1A1 | |
| SCHEMBL498824 | 0.82 | CYP2A6 (0.52) | CYP2A6TSHRCYP1A2PAX8ALDH1A1 | |
| SCHEMBL8418133 | 0.81 | CA1 (0.50) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL152855 | 0.81 | CYP2A6 (0.50) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL3224172 | 0.79 | CYP1A2 (0.48) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL3209447 | 0.79 | CYP1A2 (0.48) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 | |
| Lithium SCHEMBL31255851 | 0.79 | CYP1A2 (0.48) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL31214802 | 0.79 | CYP1A2 (0.48) | CYP2A6TSHRCYP1A2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| EP-3609880-A1 | LIVER X RECEPTORS (LXR) MODULATORS | Phenex-FXR GmbH (DE) | 2020-02-19 | — | — | EP | disclosed |
| CN-110546144-A | Liver X Receptor (LXR) modulators | PHENEX FXR GMBH | 2019-12-06 | — | — | CN | disclosed |
| WO-2018188795-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2018-10-18 | — | — | WO | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| CN-1256324-C | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2006-05-17 | — | — | CN | disclosed |
| CN-1538955-A | Pyrrolidine derivatives as factor Xa inhibitors | — | 2004-10-20 | — | — | CN | disclosed |
| EP-1104424-B1 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6489471-B1 | A PROCESS OF SYNTHESIZING A CARBAPENEM COMPOUND OF FORMULA (6) IS DISCLOSED, WHEREIN R REPRESENTS H OR METHYL, P AND P* INDEPENDENTLY REPRESENT H OR PROTECTING GROUPS AND EACH R.SUP.1 IS INDEPENDENTLY SELECTED FROM: H, HALO, OH, OP | MERCK & CO., INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1104424-A4 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | MERCK & CO INC (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1104424-A1 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | Merck & Co., Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-0981522-A1 | PROCESS FOR SYNTHESIZING CARBAPENEM INTERMEDIATES | Merck & Co., Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1999065921-A1 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | MERCK & CO., INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5908936-A | Process for synthesizing carbapenem intermediates | MERCK & CO., INC. (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1998051677-A1 | PROCESS FOR SYNTHESIZING CARBAPENEM INTERMEDIATES | MERCK & CO., INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | CYP2A6 396/4885TSHR 136/4885CYP1A2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.